Adult acute leukaemia - A retrospective study of 66 consecutive patients

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 3, 1997, Pages 301-306

  Shapiro, J ^a   Brown, S ^a   Briggs, P ^a   Stanley, R ^a   Griffiths, J ^a   Brodie, G ^a   Richardson, G ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b NONE   (Australia)

Author keywords

Acute leukaemia; Chemotherapy; Elderly; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CEFTAZIDIME; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISOLONE; RETINOIC ACID; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PATIENT SELECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030739316     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb01982.x     Document Type: Article

References (38)

1. Giles G, Farrugia H, Silver B, Staples M. Cancer in Victoria 1982-1987. Melbourne: Anti-Cancer Council of Victoria, 1992.
2. Scheinberg D, Maslak P, Weiss M. Acute leukaemia. In: Devita V, Rellman S, Rosenberg S (Eds). Principles and practice of oncology. 5th edn. Philadelphia: J. B. Lippincott Co., 1997.
3. Mayer J, Davis R, Schiffer C et al. Intensive post-remission chemotherapy in adults with acute myeloid leukaemia. N Engl J Med 1994; 331: 896-903.
4. Stone RM, Berg DT, George SL et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. N EnglJ Med 1995; 332: 1671-7.
5. Kantarjian H, Walters R, Keating M et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard and high-risk acute lymphoblastic leukaemia. J Clin Oncol 1990; 8: 994-1004.
6. Hussein KK, Dahlberg S, Head D et al. Treatment of acute lymphoblastic in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 5-63.
7. Gottlieb AJ, Weinberg V, Ellison RR et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukaemia: A prospective randomised trial by Cancer and Leukaemia Group B. Blood 1984; 64: 267-74.
8. Stone R, Mayer R. The approach to the elderly patient with acute myeloid leukaemia: In Hematol Oncol Clin North Am 1993; 7: 65-77.
9. Copplestone J, Prentice A. Acute myeloblastic leukaemia in the elderly. Leuk Res 1988; 12: 617-25.
10. Baudard M, Marie JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.
11. Lowenberg B, Zittoun R, Kerkhofs H et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia, A randomised phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia Group. J Clin Oncol 1989; 7: 1268-74.
12. Walters R, Kantarjian H, Keating M et al. Intensive treatment of acute leukaemia in adults 78 years of age and older. Cancer 1987; 60: 149-55.
13. Yates J, Glidewell O, Wiernik P et al. Cytarabine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukaemia. A CALGB study. Blood 1982; 60: 454-62.
14. Bernard P, Lacombe F, Reiffers J et al. Relationship between patient's age, bone marrow karyotype and outcome of induction therapy in acute myelogenous leukaemia. Am J Hematol 1985; 18: 153-8.
15. Rai K, Holland J, Glidewell O et al. Treatment of acute myelocytic leukaemia: a study by Cancer and Leukaemia Group B, 1981; 58: 1203-12.
16. Ellison R, Mick R, Cuttner J et al. The effects of post-induction intensification treatment with cytarabine and daunorubicin in adult acute lymphobiotic leukaemia: A prospective randomised clinical trial by Cancer and Leukaemia group B. J Clin Oncol 1991; 9: 2002-15.
17. Evenson S, Brinch L, Stavern P et al. Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy. J Intern Med 1992; 232: 433-7.
18. Bishop JF, Lowenthal RM, Joshua D et al. Etoposide in acute nonlymphocytic leukaemia. Blood 1990; 75: 27-32.
19. Neugut AI, Robinson E, Nieves J et al. Poor survival of treatment-related acute nonlymphocytic leukaemia. JAMA 1990; 264: 1006.
20. Bishop JF, Matthews JP, Young GA et al. The influence of induction chemotherapy dose and dose-intensity on the duration of remission in acute myeloid leukaemia. Australian Leukaemia Study Group. Leuk Lymph 1994; 15: 79-84.
21. Bishop JF, Matthews JP, Young GA et al. A randomised study of high-dose cytarabine in induction in acute myeloid leukaemia. Blood 1996; 87: 1710-7.
22. Young JW, Papadopolous EB, Cunningham I et al. T-cell depleted allogeneic bone-marrow transplantation in adults with acute nonlymphocytic leukaemia in first remission. Blood 1992; 79-3380.
23. Dombret H, Chastang C, Fenaux P et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenos leukaemia. N Engl J Med 1995; 332: 1678-83.
24. Kahn B, Begg C, Mazza J et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukaemia in the elderly. J Clin Oncol 1984; 2: 865-70.
25. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325: 164-70.
26. Kantarjian HM, Estey EH, O'Brien S et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony stimulating factor in the treatment of patients with acute lymphocytic leukaemia. Blood 1992; 79: 876-81.
27. Rowe JM, Anderson JW, Mazza JJ et al. A randomised placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukaemia: a study of the Eastern Cooperative Oncology Group. Blood 1995; 86: 457.
28. Hamblin TJ. Disappointments in treating acute leukaemia in the elderly. N Engl J Med 1995; 332: 1712-3.
29. Buchner T, Heinecke A. The role of prognostic factors in acute myeloid leukaemia. Leukemia 1996; 10 (Suppl. 1): S28-9.
30. Haferlach T. More individual markers are necessary for patients with acute myeloid leukaemia (AML). Does cytomorphology or cytogenetics define the biological entity? Leukemia 1996; 10 (Suppl. 3): S5-9.
31. Johnson PRE, Liu Yin JA. Acute myeloid leukaemia in the elderly: Biology and treatment. Br J Haematol 1993; 83: 1-6.
32. Bow EJ, Sutherland JA, Kilpatrick MG et al. Therapy of untreated acute myeloid leukaemia in the elderly: Remission-induction using a non-cytarabine containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14: 1345-52.
33. Rees J, Gray R, Swirsky D et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236-41.
34. Preisler H, Davis R, Kirshner J et al. Comparison of three remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukaemia: A Cancer and Leukaemia Group B study. Blood 1987; 69: 1141-9.
35. Esterhay R, Wiernik P, Grove W et al. Moderate dose methotrexate, vincristine, asparaginase and dexamethasone for treatment of adult acute lymphocytic leukaemia. Blood 1982; 59: 334-45.
36. Bishop J, Joshua D, Lowenthal R et al. A phase I/II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute nonlymphocytic leukaemia. Aust NZ J Med 1986; 16: 48-51.
37. Huang M, Ye Y, Chai J et al. Use of all trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 1988; 72: 567-73.
38. Chessels J, Bailey C, Wheller K et al. Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X. Lancet 1992; 340: 565-8.